Value of 25 mcg Cortrosyn Stimulation Test
Condition: Adrenal Insufficiency
MeSH terms: Adrenal Insufficiency
Study type: Interventional

Summary: 
      The diagnosis of secondary AI is vital to prevent catastrophic events in patients. An optimal
      test should have a very low margin of error with high sensitivity and specificity, be easy
      and safe to administer, and have distinct cut off values. Both 1 ug and 250 ug doses have
      their limitations. Based on our experience over the past six years, we hypothesize that 25 ug
      ACTH stimulation test may eliminate some of the shortcomings of the LDST (1 ug) and SDST (250
      ug). This is supported by our preliminary data and the study by Oelkers et al, which looked
      at ACTH levels following various doses of cortrosyn injections.

      Therefore we propose a head to head comparison of 25 ug, 250 ug and 1 ug dose using ITT as
      gold standard.
    

Detailed description: 
      The study consisted of two groups of adult patients 18 to 65 years of age. The first group
      (G1, n=10) included patients with hypothalamic/pituitary disease with at least one pituitary
      axis deficiency other than ACTH deficiency. The patients had the following diagnoses:
      acromegaly (n=1), prolactinoma (n=2), non-secreting pituitary macroadenomas (n=3), pituitary
      cholesterol granuloma (1), uncharacterized pituitary stalk lesion(1),recurrent null cell
      adenoma(1) and craniopharyngioma (n=1). The second group (G2, n=12) comprised healthy
      volunteers. The three CSTs and ITT were done in random order and separated by a median of 22
      days (range, 2 - 64 days) from each other. Cortisol levels were measured at 30 and 60 minute
      (min) during CSTs. A peak cortisol cut-off of 18 μg/dl was used as the pass criterion during
      ITT. The result of total cortisol levels during ITT were used to determine free cortisol
      cut-offs during CSTs and ITT. None of the patients had pituitary surgery within six weeks
      prior to enrollment and none of the women were on estrogen.

      Patients in G1 had to be on at least 3 months of stable hormone replacement for hormone
      deficiencies. All control subjects (G2) had normal TSH, free T4 and prolactin levels. All
      premenopausal women in the control group had a history of regular, age appropriate menses and
      none took birth control pills within 3 months of study entry. Postmenopausal subjects had
      appropriately elevated FSH concentration. All men in the control group had normal FSH and
      total testosterone levels.

      Exclusion criteria included: inability of subject to give an informed consent, pregnancy,
      patients with diabetes mellitus type 1 and type 2, any pituitary insult such as pituitary
      surgery in the past 6 weeks, elevated alanine aminotransferase (ALT) or aspartate
      aminotransferase (AST) more than 3 times the upper limit of normal, renal failure (defined as
      serum creatinine more than 2 mg/dl), history of malignancy in the last 5 years, severe acute
      illness and patients on opioid (fentanyl, oxycodone, hydrocodone, acetaminophen/hydrocodone)
      treatment. In addition, patients with a history of coronary artery disease, cerebrovascular
      disease, congestive heart failure, arrhythmias, or seizure disorder, were excluded due to the
      potential risk during ITT.

      Study procedures: Patients with HPA axis disorders and control subjects interested in the
      study were contacted by the research team for a screening interview. A complete medical
      history was obtained for each study participant. For female participants, a reproductive
      history was taken. All women in reproductive age group had a negative urine pregnancy test.

      All study participants were instructed to fast overnight for 12 hours prior to testing. Six
      patients were on glucocorticoid replacement and were instructed to hold their medication for
      24 hours prior to their dynamic testing. All the tests were conducted at the Clinical
      Research Unit on site at the Cleveland Clinic. The study was approved by the Cleveland Clinic
      Institutional Review Board. All subjects signed an informed consent.

      Cosyntropin Stimulation tests: The 250 µg cosyntropin vial was reconstituted with 1 ml of
      0.9% saline and used the same day. 25 µg cosyntropin was prepared by reconstituting the 250
      µg vial with 1 ml of 0.9% saline and withdrawing 0.1 ml for each injection. The unused
      reconstituted cosyntropin vials were discarded at the end of the day. 1 µg cosyntropin was
      prepared by diluting the 250 µg in 250ml of 0.9% saline and withdrawing 1ml for intravenous
      injection. Reconstituted solution for 1 µg dose was refrigerated and used for up to a month.
      During the CSTs, sFC and TC levels were drawn at baseline (t=0 min) and then at 30 and 60 min
      after 1µg (IV), 25 µg (IM) and 250µg (IM) cosyntropin doses.

      ITT: The test was initiated between 0800 and 0900 hrs, after an overnight fast. Regular human
      insulin 0.10 - 0.15 units /kg was administered intravenously, with target blood glucose less
      than 40 mg/dL. Additional insulin bolus was administered, if needed, to achieve the target
      glucose value. Administration of oral or intravenous dextrose was allowed if the subject
      developed signs of symptomatic hypoglycemia. Blood glucose levels were checked at 0, 15, 30,
      45, 60, 90 and 120 min and sFc and TC were drawn at 0, 30, 45, 60, 90 and 120 min.

      Assays: The screening labs for control subjects TSH, free T4, prolactin and complete
      metabolic profile and bedside blood glucose tests were done at the Cleveland Clinic lab. The
      screening labs for FSH, Testosterone, and samples of TC and sFC were analyzed at Quest
      Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA.

      TC was measured using Liquid Chromatography Mass Spectrometry (LCMS). The intra assay
      coefficient of variation (CV) were 3.0-4.6% at 15.9 and 202.7 µg /dl, respectively. The
      inter-assay CV were 4.8 and 7.6% at 15.2 and 189.9 µg /dl, respectively. sFC was measured
      using LCMS after separating bound and unbound cortisol by equilibrium dialysis. The intra
      assay CVs were 7.4 and 9.3 % at 0.36 and 2.17 µg /dl, respectively. The inter-assay CVs were
      9.4 and 9.8% at 0.36 and 2.17 µg/dl, respectively.

      Statistical analysis: Patient groups were compared on categorical factors using Pearson
      chi-square tests and Fisher exact tests. Continuous measures were evaluated using Wilcoxon
      rank sum tests. Sensitivity(SE) and specificity(SP) for each of the CSTs were estimated using
      optimal cut-offs from ROC curves, with respect to ITT as the gold standard. Youden's Index,
      which identifies the largest combination of SE and SP for each test was used to identify the
      optimal cut-off for each test. Tests were compared on SE and SP using McNemar's test.
      Pearson's correlation coefficient was used to measure the strength of association of peak
      cortisol levels among pairs of testing methods. Ninety-five percent confidence intervals were
      produced for all the correlation, SE, and SP estimates. Comparisons of the correlations were
      performed using the methods by Meng, Rosenthal, and Rubin (1992) to compare the correlations
      and calculate 95% confidence intervals for the difference among the tests [17]. Lower bounds
      of these intervals above a zero value was considered statistically significant evidence that
      the 25-µg test is a better test, while lower bounds at least as high as -0.15 was used to
      determine non-inferiority at those respective margins. Analyses were performed using R
      software (version 3.1; Vienna, Austria) and SAS software (version .3; Cary, NC).
    

Intervention name(s): 1 ug ACTH stimulation test; 250 ug ACTH stimulation test; 25 ug Cortrosyn stimulation test; Insulin tolerance test
Intervention type(s): Procedure; Procedure; Procedure; Procedure
Intervention description(s): 1 ug cortrosyn dose; ACTH stimulation test will be done using 250 ug cortrosyn dose; ACTH stimulation test using a 25 ug cortrosyn dose; subjects will undergo an insulin tolerance test
Intervention MeSH terms: Adrenocorticotropic Hormone; Melanocyte-Stimulating Hormones; Cosyntropin; beta-Endorphin
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: Every participant underwent the four interventional tests in random sequence
Masking: None (Open Label)
Primary purpose: Diagnostic